How Alpelisib Works: Targeting the PI3K Alpha Isoform

The Pathway Alpelisib Interrupts

Class I PI3K converts the membrane lipid PIP2 to PIP3, which recruits AKT to the membrane and activates it, driving growth, survival and metabolism through mTOR and other effectors. PTEN reverses the reaction. PIK3CA-activating mutations (hotspots in the helical and kinase domains) raise pathway output.

Alpelisib binds the ATP site of the p110-alpha catalytic subunit and blocks the lipid kinase reaction.

Why Isoform Selectivity

There are four class I PI3K catalytic isoforms (alpha, beta, delta, gamma) with distinct roles. Pan-PI3K inhibitors block all of them and were limited by toxicity (rash, liver enzyme elevations, mood effects) without clearly better efficacy.

Alpelisib concentrates inhibition on the isoform that PIK3CA mutations activate, which improves the therapeutic window but does not eliminate on-target metabolic effects.

The Hyperglycaemia Is Mechanism-Based

PI3K-alpha is the isoform that mediates insulin signalling. Inhibiting it causes insulin resistance, raising blood glucose; the pancreas responds with more insulin, which can feed back to reactivate PI3K in the tumour.

Hyperglycaemia is therefore expected, is monitored from the start, and is managed with metformin and other measures. It is also a reason ketogenic-diet and SGLT2-inhibitor strategies are being studied alongside PI3K-alpha inhibition.

Patient Selection and Resistance

Benefit in the SOLAR-1 trial was confined to tumours with a PIK3CA mutation, detected in tumour tissue or circulating tumour DNA, so a validated test is required. Resistance develops through PTEN loss, AKT1 or other pathway mutations, and reactivation via the beta isoform or upstream receptors.

Newer PI3K-alpha inhibitors and mutant-selective agents aim to improve tolerability and durability.

Managing Hyperglycaemia and Other Toxicity

Because hyperglycaemia is expected, fasting glucose and HbA1c are checked before starting and blood glucose is monitored closely in the first weeks. Metformin is the usual first treatment for treatment-emergent hyperglycaemia, with additional agents or an endocrinology referral if it is not controlled; severe elevations require holding the drug. Poorly controlled pre-existing diabetes is a relative contraindication.

The other dose-limiting toxicity is rash, which prophylactic non-sedating antihistamines reduce. Diarrhoea, mouth sores, nausea and fatigue are common, and pneumonitis is rare. Alpelisib is taken once daily with food.

Testing: Tissue and Liquid Biopsy

A PIK3CA mutation can be identified in tumour tissue or in circulating tumour DNA from a blood sample. Liquid biopsy is convenient and samples multiple tumour sites at once, but a negative plasma result does not exclude a mutation, so tissue testing is recommended when plasma is negative.

The relevant mutations cluster at known hotspots in the helical (E542K, E545K) and kinase (H1047R) domains, and companion diagnostics are validated for a defined list. A PIK3CA change outside that list, or seen only at a low allele fraction, needs cautious interpretation.

Key Takeaways

• ·Alpelisib blocks the p110-alpha PI3K subunit encoded by PIK3CA, the pathway's most mutated gene.
• ·Isoform selectivity widens the therapeutic window versus pan-PI3K inhibitors.
• ·Hyperglycaemia is an on-target effect requiring monitoring; PTEN loss and AKT1 mutation drive resistance.